Compare Gilead Sciences, Inc. (GILD) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Gilead Sciences, Inc. trades at $155.6 (market cap $190.38B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: Gilead Sciences, Inc. is far larger — about 194.8× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Gilead Sciences, Inc. pays a 2.14% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 112 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| GILD | MRVI | |
|---|---|---|
Market Cap | $190.38B | $977.37M |
Volume | 5,758,183 | 2,742,564 |
Sector | Health | Health |
52-Week High | $155.80 | $9.00 |
52-Week Low | $117.85 | $2.83 |
Typical Hold Time | 112 Days | 0 Days |
Enterprise Value | $213.45B | $1.08B |
Dividend Yield | 2.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.92, down 1.67% on the day, with strong analyst support (67% buy ratings) and a $153.13 consensus price target. Recent quarterly earnings beat expectations despite a Q2 loss, while revenue growth remains steady. Technical indicators show a bullish trend with support at $147-149 and resistance at $152-154. The company continues expanding HIV treatment access through recent PAHO partnerships.
GILD presents a mixed fundamental picture with strong revenue growth but negative net margins. The stock offers upside to analyst targets but faces execution risks in oncology pipeline development and competitive pressures. Recent institutional selling and high debt levels warrant monitoring, though expanding HIV franchise provides stable cash flow foundation.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
